Orofacial Pain, Temporomandibular Joint Disorder & Neurobiology | National Institute of Dental and Craniofacial Research

Orofacial Pain, Temporomandibular Joint Disorder & Neurobiology

NIDCR is PRIMED to move AHEAD with IMPACT: Institute Awards $14 Million to Tackle Unsolved Clinical Challenges

A photo of the physician chatting with her staff while treating a patient

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

RFA-NS-24-019

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

PAR-24-063

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

PAR-24-043

Looking Forward to Greater IMPACT on Temporomandibular Disorders

In Brief:

HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)

RFA-NS-23-007

HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)

RFA-NS-23-006

Notice of NIDCR Participation in RFA-NS-23-007, "HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Not Allowed)"

NOT-DE-24-005

Notice of NIDCR Participation in RFA-NS-23-006, "HEAL INITIATIVE: Development of Therapies and Technologies Directed at Enhanced Pain Management (R43/R44 Clinical Trial Not Allowed)"

NOT-DE-24-004

NIDCR Award for Sustaining Outstanding Achievement in Research (SOAR) (R35 Clinical Trial Not Allowed)

RFA-DE-24-006